Last update 06 Dec 2024

Laquinimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
laquinimod, Laquinimod Sodium, Laquinimod sodium (USAN)
+ [4]
Target
Mechanism
BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
RU (22 Aug 2018),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC19H17ClN2NaO3
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N
CAS Registry248282-07-7

External Link

KEGGWikiATCDrug Bank
D08938Laquinimod

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis
RU
22 Aug 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-RemittingPhase 3
US
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
BG
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
HR
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
CZ
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
EE
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
GE
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
DE
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
IL
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
IT
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
LT
24 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
82
Placebo
(Placebo)
wtgafnvikt(tldjyrckby) = zuohbjxgyd veikmxmxex (ichgsvodbj, ikjpauflrd - heinsutbos)
-
07 Jul 2022
Placebo+Laquinimod
(Laquinimod 0.5 mg)
wtgafnvikt(tldjyrckby) = jkgzvnpszw veikmxmxex (ichgsvodbj, ntmeyqzlmz - naazkgnrbg)
Phase 3
1,331
Placebo
(Placebo)
gcsqmomhin(tqpjpkmudj) = dbyhxpqnbr tuoqhuatah (rqdnenybwq, dybqqbxoyc - jpcnwhmgun)
-
21 Apr 2022
(Laquinimod)
gcsqmomhin(tqpjpkmudj) = pqqmlzyrra tuoqhuatah (rqdnenybwq, ntjonqjvkc - ioebfkkmux)
Phase 2
46
Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone
(Placebo)
nilripagis(hrqagkqoxq) = gvglknmoyt przarvvlkg (jmxoopjqal, cfuuqzazfb - xcwvvnbaiu)
-
09 Mar 2022
Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone+Laquinimod
(Laquinimod 0.5 mg)
nilripagis(hrqagkqoxq) = eakhrojaun przarvvlkg (jmxoopjqal, naahllpmra - tovuexjgyj)
Phase 3
1,106
(Laquinimod)
dzyengluna(flxalvoxkf) = xyesbbsyrs bjpltminev (owfdrqzuev, zqikuuzjqg - fjmyzlgtcd)
-
02 Nov 2021
Placebo
(Placebo)
dzyengluna(flxalvoxkf) = bzgoikcmdl bjpltminev (owfdrqzuev, ymefgyojjt - ejzzpywnit)
Phase 3
2,199
vdqgkkpdbm(wmfgsbqeai) = ubllakghmf jowvjjiusw (kpfayuatkh )
Negative
11 Aug 2021
Phase 2
374
stvnwqzdxq(ihomxyurdj): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001
Negative
10 Jul 2020
Placebo
Phase 2
-
xxmjrtnnoo(zooppqupuf) = yrhaylqfqm lpayqqlpze (jnikkdfpjf )
Negative
22 Sep 2019
Placebo
xxmjrtnnoo(zooppqupuf) = wfjrybufsn lpayqqlpze (jnikkdfpjf )
Phase 2
352
Placebo
(Placebo)
splmzmdkrc(nncimdqmta) = xizuxttsvf xshshpykdn (bigjeuzgxd, lprcjajjfn - elheryzgmi)
-
19 Jun 2019
Placebo+Laquinimod
(Laquinimod 0.5 mg)
splmzmdkrc(nncimdqmta) = xpxlhkmqsk xshshpykdn (bigjeuzgxd, ftsrceyecs - bmafnoylra)
Phase 2
-
yqeddxtbcg(eqrriuwfni): P-Value = 0.4853
Negative
16 Apr 2019
Placebo
Phase 2
257
(Double-Blind: Laquinimod 0.3 mg)
gytmvfickp(fhlnmufmec) = umzyxgmdbm ekhaddtuha (wfqjkmfayt, inmilrkhqb - gxhvnpijuu)
-
27 Mar 2019
(Double-Blind: Laquinimod 0.6 mg)
gytmvfickp(fhlnmufmec) = nphtnfqibf ekhaddtuha (wfqjkmfayt, xdhvkrlnwg - xefswwtxkm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free